Omega Diagnostics (CNSL) AI Stock Analysis

• Market Cap: £4.40M
• Dividend Yield: N/A
• Average Volume (3M): 353.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: -10.20%
• EPS Growth: 714.29%
• Country: UK
• Employees: 94
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.00
• Shares Outstanding: 237,950,650
• 10 Day Avg. Volume: 111,535
• 30 Day Avg. Volume: 353,573
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.87
• P/FCF Ratio: -51.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: 2.00 p ▼(-13.04% Downside)
• Action: Reiterated Date: 12/07/25
• Date: Action: Reiterated 12/07/25

The overall stock score is primarily influenced by the mixed financial performance and bearish technical indicators. While the valuation suggests the stock may be undervalued, significant financial and technical challenges weigh heavily on the score. The positive sentiment from leadership's share acquisitions provides a minor offset but is not enough to significantly alter the overall outlook.

Positive Factors

Balance Sheet Strength

Very low leverage and a mid-teens ROE provide durable financial flexibility. Low debt reduces bankruptcy risk and preserves capacity to fund working capital, R&D or selective M&A without stressing the capital structure, supporting resilience across economic cycles.

Negative Factors

Declining Revenue

Sustained top-line contraction undermines scale economics and market positioning. Persistent revenue decline reduces leverage over fixed costs, pressures unit economics, and complicates investments in product development and commercial expansion needed to restore growth.

Omega Diagnostics Business Overview & Revenue Model

Company Description

Cambridge Nutritional Sciences plc, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kit...

Read more

Cambridge Nutritional Sciences plc, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kit...

How the Company Makes Money

Omega Diagnostics generates revenue through the sale of its diagnostic products, which are marketed to hospitals, laboratories, and healthcare providers. The company has established key revenue streams from the distribution of its allergy testing ...

Read more

Omega Diagnostics generates revenue through the sale of its diagnostic products, which are marketed to hospitals, laboratories, and healthcare providers. The company has established key revenue streams from the distribution of its allergy testing ...

Omega Diagnostics Financial Statement Overview

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	8.06M	8.33M	9.77M	7.55M	8.54M	6.82M
Gross Profit	4.91M	5.00M	6.05M	3.17M	4.75M	4.00M
EBITDA	2.01M	2.20M	-73.00K	-2.65M	-382.00K	418.00K
Net Income	1.36M	1.57M	-328.00K	-3.86M	-11.33M	-2.10M
Balance Sheet
Total Assets	12.69M	13.80M	13.89M	14.40M	17.84M	29.55M
Cash, Cash Equivalents and Short-Term Investments	3.59M	4.87M	5.44M	5.12M	1.60M	5.83M
Total Debt	237.00K	349.00K	148.00K	74.00K	370.00K	2.84M
Total Liabilities	1.64M	2.39M	4.21M	4.45M	6.02M	6.16M
Stockholders Equity	11.05M	11.41M	9.68M	9.95M	11.82M	23.38M
Cash Flow
Free Cash Flow	-437.00K	-142.00K	548.00K	-3.31M	-4.71M	-5.24M
Operating Cash Flow	-166.00K	83.00K	607.00K	-3.15M	-3.23M	-2.42M
Investing Cash Flow	-482.00K	2.12M	-2.51M	5.18M	-493.00K	-2.83M
Financing Cash Flow	-233.00K	-251.00K	-265.00K	1.49M	-502.00K	11.07M

Omega Diagnostics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CNSL, the sentiment is Negative. The current price of 2.3 is above the 20-day moving average (MA) of 1.88, above the 50-day MA of 1.95, and below the 200-day MA of 2.62, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 12.09 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CNSL.

Omega Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSTL	74 Outperform	£180.94M	12.60	23.64%	3.48%	10.80%	1.75%
EKF	66 Neutral	£103.43M	55.78	3.01%	―	-1.43%	28.57%
AMS	56 Neutral	£426.75M	47.21	3.87%	1.25%	68.03%	-18.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IXI	51 Neutral	£7.18M	-7.18	-15.57%	―	13.32%	55.07%
CNSL	50 Neutral	£4.40M	-4.58	12.15%	―	-10.20%	714.29%
ABDX	45 Neutral	£20.09M	-2.69	-58.27%	―	37.39%	-126.19%